Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPMI DPA-714 PET Imaging
NCT06289582Phase 1Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Aug 2024
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of DPA-714 in Parkinson's disease (PD) (2 arms), sponsored by University of Alabama at Birmingham. Primary endpoint: Regional brain TSPO levels at 24 months. Started Aug 2024; status: recruiting.
02
Drugs
DPA-714
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06289582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06289582.